AN2 Therapeutics, Inc. (ANTX) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. AN2 Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. The company focuses on infectious diseases (Chagas disease, NTM lung disease, melioidosis) and oncology. As of the filing date, the company has no approved products and has not generated any revenue from product sales.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(9.4) million | $(12.7) million | $(26.5) million | $(43.8) million |
| Net Loss Per Share | $(0.31) | $(0.43) | $(0.88) | $(1.47) |
| Operating Expenses | $10.0 million | $14.0 million | $28.8 million | $48.2 million |
| Cash & Investments | $65.1 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $232.2 million (as of Sept 30, 2025) | |||
| Operating Cash Flow | N/A | $(24.6) million | $(44.0) million |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 28% in Q3 2025 compared to Q3 2024, and by 40% on a year-to-date basis. This is primarily due to the absence of $2.2 million in restructuring charges recorded in Q3 2024 following a ~50% workforce reduction in August 2024.
- R&D Shift: While clinical trial expenses decreased significantly due to the termination of the EBO-301 study for treatment-refractory MAC lung disease, preclinical and research study expenses increased by 527% in Q3 2025 as the company prioritized its Chagas disease program (AN2-502998) and oncology targets.
- Government Funding: In June 2025, the NIAID notified the company it would not exercise certain remaining options on a contract, reducing the total potential funding from $18.3 million to $9.3 million. However, the company recorded $3.5 million in grant income as a reduction of R&D expenses YTD 2025.
- Equity Transactions: In June 2025, the company exchanged 2,952,000 shares of common stock for pre-funded warrants with existing stockholders. No cash consideration was received.
Guidance, Outlook, and Risks
- Liquidity: Management believes cash, cash equivalents, and investments of $65.1 million are sufficient to fund operations for at least 12 months from the filing date. The company expects to incur substantial additional losses until product commercialization.
- Development Pipeline:
- Chagas Disease: Phase 1 start-up activities initiated in May 2025; first cohort dosing completed in August 2025. Phase 2 proof-of-concept expected in 2026.
- Oncology: Anticipates advancing the first oncology compound into development in early 2026.
- Melioidosis: Discussions are underway with the U.S. government to fund Phase 2 development of epetraborole.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal control over financial reporting (specifically regarding the control environment, period-end reporting, and IT general controls) that were previously identified and remain unremediated.
- Risks: Key risks include the failure of clinical trials, inability to raise additional capital, dependence on third-party manufacturers, and the potential for bacterial resistance to product candidates.
Investor Verification Checklist
- Verify the sufficiency of the $65.1 million cash runway given the high burn rate and lack of revenue.
- Monitor the status of the material weaknesses in internal controls over financial reporting and the remediation plan.
- Track the progress of the Phase 1 trial for AN2-502998 (Chagas disease) and the timeline for Phase 2 initiation.
- Review the impact of the reduced NIAID contract funding ($9.3 million total) on the melioidosis development timeline.
- Assess the dilution impact of the 2,952,000 pre-funded warrants issued in June 2025.